<DOC>
	<DOCNO>NCT02139124</DOCNO>
	<brief_summary>The purpose randomize , placebo-controlled , double-blind , parallel group study evaluate clinical efficacy safety PRC-063 adult ADHD</brief_summary>
	<brief_title>The Efficacy Safety PRC-063 Adult ADHD Patients</brief_title>
	<detailed_description>This study randomize , phase III , multicenter , placebo-controlled , parallel-group , forced-dose titration adult subject ( 18 year age old ) ADHD randomize PRC-063 ( 25 , 45 , 70 100 mg ) placebo four week double-blind evaluation safety efficacy . The study four phase : ( 1 ) screen 1-week washout ; ( 2 ) baseline double-blind , forced-dose titration 2-week period ; ( 3 ) double-blind evaluation 2-week period ; ( 4 ) 14-day safety follow-up . Subjects require visit site 6 time 5 week period . Screening Washout : Subjects screen establish eligibility study participation . Subjects meet eligibility requirement undergo ADHD medication washout , applicable .</detailed_description>
	<criteria>Male nonpregnant , nonnursing female least 18 year age meeting local , legal definition adult . ADHD diagnosis , inattentive , hyperactive/impulsive combine , define Diagnostic Statistical Manual Mental Disorders , 5th Edition ( DSM5 ) base clinician assessment use multiple informant structure interview . Unsatisfied current pharmacological therapy treatment ADHD currently receive pharmacological therapy ADHD . Inclusion subject naïve pharmacological therapy ADHD permit . Female subject must one following : a. surgically sterile prior screening ; b. postmenopausal ; c. childbearing potential , abstinent willing use reliable method contraception , oral contraceptive , two barrier method , barrier method plus spermicidal agent . Female subject ChildBearing Potential ( FOCP ) must negative serum βhCG pregnancy test screening . Minimum level intellectual functioning , determine Intelligence Quotient ( IQ ) score 80 base WASI . Mentally physically competent sign inform consent document indicate understand purpose procedure require study willing participate study . Able willing comply study procedure entire length study , include successful swallow test empty 100 mg capsule . Having allergy methylphenidate amphetamine history serious adverse reaction methylphenidate . Known nonresponsive methylphenidate treatment . Nonresponse define methylphenidate use various dos phase least four week dose little clinical benefit . Being diagnosed history stroke , epilepsy , migraine headache ( great 1 instance every two month ) , glaucoma , thyrotoxicosis , tachyarrhythmias severe angina pectoris serious unstable medical illness . Subjects control stable asthma diabetes permit . Elevated blood pressure , define value 89 diastolic 139 systolic , assessed Visit 1 . Clinically significant ECG abnormality , assess Visit 1 . Clinically significant laboratory abnormality , assess Visit 1 . Currently receive guanethidine , pressor agent , MAO inhibitor , coumarin anticoagulant , anticonvulsant ( e.g . phenobarbital , phenytoin , primidone ) , phenylbutazone , tricyclic antidepressant ( e.g . imipramine , desipramine ) , selective serotonin reuptake inhibitor ( SSRIs ) herbal remedy ( unless stable dose 4 week ) . Subject known history symptomatic cardiovascular disease , advanced arteriosclerosis , structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , coronary heart disease , transient ischemic attack stroke serious cardiac problem may place subject increase vulnerability sympathomimetic effect stimulant drug . Subject know family history sudden cardiac death ventricular arrhythmia . Subjects currently consider suicide risk investigator . Having primary diagnosis schizophrenia , schizoaffective disorder , primary affective disorder , schizotypal personality , major depression , bipolar disorder , generalize anxiety , borderline personality disorder , antisocial personality another unstable psychiatric condition require treatment , assess structure interview conduct Visit 1 . Having history suspect physiological dependence ( exclude nicotine ) narcotic analgesic psychoactive drug ( include barbiturate , opiate , cocaine , cannabinoids , amphetamine benzodiazepine ) . Excessive consumption alcohol ( consumes alcohol quantity great 15 drink per week ; 1 drink define 360 mL/12 oz . beer , 120 mL/4 oz . wine , 30 mL/1 oz . hard liquor ) , history ( within previous 6 month ) alcohol abuse . Currently ( within 30 day plan start treatment ) receive investigational drug use experimental medical device . Homeless .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>